ArticleEndocrine2025
Aortic valve stenosis in high-Lipoprotein(a) patients: the role of lipoprotein apheresis.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipoprotein(a) in cardiovascular disease: pathophysiology, residual risk, and emerging therapeutic strategies.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNowadays, despite the new lipid-lowering drugs, lipoprotein apheresis (LA) maintains its therapeutic role in severe hypercholesterolemia in subjects without achieved LDL-cholesterol target on maximally tolerated lipid-lowering therapies and in subjects with high levels of lipoprotein (a) (> 50 mg/dl). The coexistence of both familial hypercholesterolemia and elevated-Lp(a) increase the risk of cardiovascular events and are associate with aortic valve stenosis.
objectivesThe aim of this study was to evaluate the progression of aortic valve disease in subjects of chronic LA treatment in relation to the presence of high levels of lipoprotein (a).
methodsTo evaluate the therapeutic role of LA in aortic valve stenosis progression related to high-lipoprotein (a), patients with more than 3 years of chronic LA therapy were retrospective evaluated: have been identified 47 patients (mean age 52 ± 12 years, male 72%) with suitable echocardiographic follow-up.
resultsSubjects with high-Lp(a) (30/47) had a more severe aortic valve disease at the beginning of LA treatment (mild/moderate aortic valve disease 7/30 vs. 0/17; p < 0.05). During the follow-up (10 [5-14] years) a progressive increase in aortic peak velocity (baseline 1.45 ± 0.42 m/sec vs. follow-up 1.78 ± 0.92 m/sec, p < 0.001) was recorded in overall subjects. Moreover, in subjects with high-Lp(a) the progression of aortic disease is similar to subjects with normal lipoprotein(a) values: Δ aortic peak velocity (m/sec) respectively 0.14 [0.30–0.55] vs. 0.20 [0.07–0.39]. Two patients with moderate baseline aortic stenosis required valve replacement, even after 15 years from the start of LA therapy.
conclusionsEven in the era of new lipid-lowering therapies, patients with high-Lp(a) may not be identified early and develop aortic valve disease. However, LA remains a safe and life-saving treatment with a comparable aortic valve stenosis progression regardless of the Lp(a) values.
Indexed as
Identifiers
41460572What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.